Study details
Enrolling now
Naltrexone in AUD Reward Drinkers
University of Pennsylvania
NCT IDNCT05028062ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 5.8 years
Ages
18–65
Locations
1 site in PA
What this study is about
This trial is testing whether XR-NTX, a long-acting injectable naltrexone, helps reward drinkers with Alcohol Use Disorder reduce heavy drinking compared to a placebo. Participants will receive monthly injections of either XR-NTX or a matching placebo along with medical management sessions. It lasts for 2125 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Medical Management
- 2.Receive Placebo intramuscular injection
- 3.Receive XR-NTX 380 mg, intramuscular injection
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
injection
Body systems
Psychiatry / Mental Health